fda glp-1 compounding enforcement october 2025 is short-sighted on GLP-1s Navigating GLP-1 Compounding: FDA and

Pomegranate serves all 50 states

GLP-1R = appetite suppression

Richardson M, Garner P, Donegan S

Important Safety Reminders Medical Supervision Required: AOD-9604 should only be used under qualified medical supervision Baseline and monitoring laboratory testing is recommended Individual contraindications and health status must be evaluated AOD-9604 is not FDA-approved for any indication Contraindications and Precautions: Pregnancy and breastfeeding (no safety data available) Active malignancy (discuss with oncologist) Pediatric use (not studied in children) Significant organ dysfunction (limited safety data) Report Concerns: Any unexpected symptoms or adverse effects should be reported to your healthcare provider promptly

,